Cargando…

Identifying treatment response to antihypertensives in patients with obesity-related hypertension

BACKGROUND: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. METHODS: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrover, Ilse M., Dorresteijn, Jannick A. N., Smits, Jodine E., Danser, A. H. Jan, Visseren, Frank L. J., Spiering, Wilko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654008/
https://www.ncbi.nlm.nih.gov/pubmed/29085669
http://dx.doi.org/10.1186/s40885-017-0077-x
_version_ 1783273322723672064
author Schrover, Ilse M.
Dorresteijn, Jannick A. N.
Smits, Jodine E.
Danser, A. H. Jan
Visseren, Frank L. J.
Spiering, Wilko
author_facet Schrover, Ilse M.
Dorresteijn, Jannick A. N.
Smits, Jodine E.
Danser, A. H. Jan
Visseren, Frank L. J.
Spiering, Wilko
author_sort Schrover, Ilse M.
collection PubMed
description BACKGROUND: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. METHODS: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. RESULTS: Systolic BP response to aliskiren was higher in patients with a BMI > 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (−21 mmHg versus -4 mmHg). In patients with a hsCRP > 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (−15 mmHg versus −7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was −13 mmHg when heart rate > 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. CONCLUSION: In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. TRIAL REGISTRATION: NCT01138423. Registered June 4th, 2010.
format Online
Article
Text
id pubmed-5654008
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56540082017-10-30 Identifying treatment response to antihypertensives in patients with obesity-related hypertension Schrover, Ilse M. Dorresteijn, Jannick A. N. Smits, Jodine E. Danser, A. H. Jan Visseren, Frank L. J. Spiering, Wilko Clin Hypertens Research BACKGROUND: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. METHODS: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. RESULTS: Systolic BP response to aliskiren was higher in patients with a BMI > 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (−21 mmHg versus -4 mmHg). In patients with a hsCRP > 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (−15 mmHg versus −7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was −13 mmHg when heart rate > 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. CONCLUSION: In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. TRIAL REGISTRATION: NCT01138423. Registered June 4th, 2010. BioMed Central 2017-10-24 /pmc/articles/PMC5654008/ /pubmed/29085669 http://dx.doi.org/10.1186/s40885-017-0077-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Schrover, Ilse M.
Dorresteijn, Jannick A. N.
Smits, Jodine E.
Danser, A. H. Jan
Visseren, Frank L. J.
Spiering, Wilko
Identifying treatment response to antihypertensives in patients with obesity-related hypertension
title Identifying treatment response to antihypertensives in patients with obesity-related hypertension
title_full Identifying treatment response to antihypertensives in patients with obesity-related hypertension
title_fullStr Identifying treatment response to antihypertensives in patients with obesity-related hypertension
title_full_unstemmed Identifying treatment response to antihypertensives in patients with obesity-related hypertension
title_short Identifying treatment response to antihypertensives in patients with obesity-related hypertension
title_sort identifying treatment response to antihypertensives in patients with obesity-related hypertension
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654008/
https://www.ncbi.nlm.nih.gov/pubmed/29085669
http://dx.doi.org/10.1186/s40885-017-0077-x
work_keys_str_mv AT schroverilsem identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension
AT dorresteijnjannickan identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension
AT smitsjodinee identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension
AT danserahjan identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension
AT visserenfranklj identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension
AT spieringwilko identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension